ASX:IMMPharmaceuticals, Biotechnology & Life SciencesBiotechnology
IMMUTEP ORD
$0.070
$0.004 (5.41%)
Day Range
$0.070 - $0.072
52 Week Range
$0.028 - $0.470
Volume
48.53M
Avg Volume (10D)
106.27M
Market Cap
$103.16M
Price Chart
Market Statistics
Open$0.072
Previous Close$0.074
Day High$0.072
Day Low$0.070
52 Week High$0.470
52 Week Low$0.028
Valuation
Market Cap103.16M
Shares Outstanding1.47B
Price to Book1.04
Trading Activity
Volume48.53M
Value Traded3.44M
Bid$0.070 × 395,062
Ask$0.071 × 700,000
Performance
1 Day-5.41%
5 Day1.45%
13 Week-84.78%
52 Week-72.00%
YTD-83.13%
Technical Indicators
RSI (14)37.13
50-Day SMA$0.191
200-Day SMA$0.275
Latest News
Biotechnology
Immutep Granted FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma
Immutep wins FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, boosting exclusivity and regulatory support as TACTI-004 winds down.
1 min read
Hot Topics
Weekly Wrap: Shares fall another 2.6% for the week as conflict worsens
ASX 200 slides 2.6% this week to 8,617 as Iran-Israel conflict lifts oil above $100; NST and SYR plunge, while EOS soars on a Middle East contract.
3 min read
Biotechnology
Immutep Discontinues TACTI-004 Phase III Trial Due to Futility
Immutep halts TACTI-004 Phase III in first-line NSCLC due to futility; shares resume trading as cash runway extends beyond Q2 CY2027.
1 min read
Biotechnology
Immutep TACTI-004 NSCLC Trial At 50% Enrolment, Paving Way for Futility Analysis
Immutep (ASX: IMM) has achieved a significant milestone, announcing 50% patient enrolment in its global Phase III TACTI-004 trial for first-line non-small ce
1 min read